ReviewBJU international2025
Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer.
Review in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.BJU international · 2026Pooled it
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.The Prostate · 2026Review
- Review
- The impact of PSMA-PET/CT on clinical decision-making in primary staging of prostate cancer.EJNMMI research · 2026Article
- [BJUI compass · 2026Article
- High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression.BJUI compass · 2026Article
- Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.BJU international · 2026Article
- PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.American journal of translational research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo provide a comprehensive review and analysis of guidelines from various professional and medical organisations regarding the use of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) as a staging scan for men with newly diagnosed intermediate-risk prostate cancer (PCa). MATERIALS AND
methodsEnglish-language guidelines and recommendations from the following associations and societies were reviewed and critically analysed: European Association of Urology (EAU), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), Canadian Urological Association (CUA), American Society for Clinical Oncology (ASCO), Society for Nuclear Medicine and Medical Imaging (SNMMI).
resultsThere is significant disagreement among guidelines regarding whether PSMA PET is a useful staging tool for men with a new diagnosis of intermediate-risk PCa. There is a stronger consensus that PSMA PET is useful in staging high-risk PCa.
conclusionWhilst there is a growing body of evidence that supports the use of PSMA PET in newly diagnosed PCa, there is significant disagreement regarding its use for men with intermediate-risk disease. Recommendations are generally weak and based on expert opinions. This is an area of considerable ongoing research, and guidelines are likely to change as new evidence emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.